Steven T. Szabo, MD, PhD, is an Assistant Professor, Department of Psychiatry and Behavioral Sciences at Duke University Medical Center in Durham, NC.
Dr. Szabo earned his PhD in Neurosciences from McGill University, Montreal, Quebec, Canada. He subsequently completed postdoctoral trainings in Psychopharmacology at the University of Florida, Department of Psychiatry, and in the Mood and Anxiety Disorders Program at the National Institutes of Mental Health (NIMH). This allowed him to detail the mechanism of action of mood stabilizers and agents like ketamine on the glutamate system. Dr. Szabo later completed medical school and prior to embarking on psychiatry residency at Duke University in 2009, he participated in the Summers of Discovery Program at the National Institutes of Environmental Health Sciences (NIEHS) to investigate environmental causes of mood dysregulation.
Dr. Szabo has been practicing psychiatry for nearly 10 years and is a Board Certified Psychiatrist at Duke University. Dr. Szabo conducts research in the Division of Translational Neuroscience and Division of Brain Stimulation and Neurophysiology. Dr. Szabo is also a member of the Mental Health Service Line and is employed as an Attending Psychiatrist in the Emergency Room at the Durham Veterans Administration Medical Center (VAMC). He is a Mental Illness Research, Education, Clinical Centers of Excellence (MIRECC) workgroup member at the Durham VAMC with special interest in developing and testing biomarkers of mental illness that focuses on post-traumatic stress disorders (PTSD) and Gulf-War illness. Training as both a neuroscientist and psychiatrist, with his longstanding interest in psychopharmacology, neurotoxicology, and experimental therapeutics have sculpted this bench to bedside approach to research and clinical care.
Dr. Szabo currently conducts fundamental science experiments with both government and industry-funded clinical trials at Duke University and Durham VAMC. He is an investigator for the NIMH sponsored Fast-Fail Trials (FAST-MAS), which is a flagship NIMH contract study employing an experimental therapeutic and biomarker approach to early phase treatment studies in patients with mood and anxiety disorders. He has published more than 40 scientific papers in peer-reviewed journals. Dr. Szabo has a passion for psychiatry resident and medical student education and is the course master for Biological Psychiatry at Duke University.